{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:51:11Z","timestamp":1785919871780,"version":"3.56.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>The role of non-selective beta-blockers (NSBBs) in patients with decompensated cirrhosis remains controversial, with conflicting evidence regarding their safety and efficacy across different stages of disease severity. This meta-analysis aimed to evaluate the association between NSBB use and mortality in patients with decompensated cirrhosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science from inception to May 2026. Studies reporting the risk of mortality associated with NSBB use in decompensated cirrhosis were included. Pooled HRs with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses were performed based on mean arterial pressure (MAP), Model for End-stage Liver Disease (MELD) score, NSBB dosage, and cirrhosis complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      24 studies comprising 120,072 patients were included. NSBB use was associated with a significant 25% reduction in mortality risk (HR = 0.75, 95%CI: 0.66\u20130.85, P &amp;lt; 0.01), albeit with substantial heterogeneity (I\n                      <jats:sup>2<\/jats:sup>\n                      = 87%). The protective effect was consistent across studies employing propensity score matching (HR = 0.72, 95%CI: 0.59\u20130.88, P &amp;lt; 0.01) and multivariable regression analyses (HR = 0.74, 95%CI: 0.61\u20130.89, P &amp;lt; 0.01) by sensitivity analysis. Subgroup analyses revealed that the mortality benefit was more pronounced in patients with consistent baseline blood pressure (BP) between groups (HR = 0.82, 95%CI: 0.89\u20130.97), MELD score \u226415 (HR = 0.72, 95%CI: 0.56\u20130.92), and those receiving low-dose NSBBs (HR = 0.74, 95%CI:0.60\u20130.91). Conversely, NSBB use was not associated with reduced mortality in patients with inconsistent baseline BP (HR = 1.25, 95%CI: 0.52\u20133.00), MELD score &amp;gt;15 (HR = 0.92, 95%CI: 0.63\u20131.35), or high-dose NSBB therapy (HR = 0.92, 95%CI: 0.64\u20131.32). The presence of ascites, spontaneous bacterial peritonitis or hepatic encephalopathy appeared to not aggravate the survival risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Decompensated cirrhosis should not be regarded as an absolute contraindication to NSBB therapy; rather, the decision to initiate treatment, particularly at a low dose, may be guided by MAP and MELD scores. Nonetheless, these findings require further validation through randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>\n                      , CRD420261406986.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1920788","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:31:13Z","timestamp":1785918673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of non-selective \u03b2 blockers with the mortality risk in decompensation cirrhosis: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Junchao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Xiamen Hospital of Traditional Chinese Medicine","place":["Xiamen, China"]},{"name":"Department of Gastroenterology, Xiamen Hospital Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Xiamen, China"]},{"name":"Department of Gastroenterology, Xiamen TCM Hospital Affiliated to Fujian University of Traditional Chinese Medicine","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Infection, the First Affiliated Hospital of Xiamen University","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaxia","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Xiamen Hospital of Traditional Chinese Medicine","place":["Xiamen, China"]},{"name":"Department of Gastroenterology, Xiamen Hospital Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Xiamen, China"]},{"name":"Department of Gastroenterology, Xiamen TCM Hospital Affiliated to Fujian University of Traditional Chinese Medicine","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.amjms.2015.11.018","article-title":"The beneficial effect of beta-blockers in patients with cirrhosis, portal hypertension and ascites","volume":"351","author":"Aday","year":"2016","journal-title":"Am. J. Med. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jhep.2022.12.005","article-title":"Beta-blockers in the era of precision medicine in patients with cirrhosis","volume":"78","author":"Albillos","year":"2023","journal-title":"J. Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2020.03.048","article-title":"Short-term hemodynamic effects of \u03b2-blockers influence survival of patients with decompensated cirrhosis","volume":"73","author":"Alvarado-Tapias","year":"2020","journal-title":"J. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","article-title":"The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis","volume":"74","author":"Arroyo","year":"2021","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/liv.13119","article-title":"Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers","volume":"36","author":"Bang","year":"2016","journal-title":"Liver Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/apt.14366","article-title":"Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation","volume":"47","author":"Bhutta","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/hep.28352","article-title":"Nonselective \u03b2-blockers do not affect mortality in cirrhosis patients with ascites: post hoc analysis of three randomized controlled trials with 1198 patients","volume":"63","author":"Bossen","year":"2016","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"FSO954","DOI":"10.2144\/fsoa-2023-0110","article-title":"Cirrhotic cardiomyopathy: a subject that's always topical","volume":"10","author":"Boudabbous","year":"2024","journal-title":"Future Sci. OA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/liv.14674","article-title":"Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD \u2265 12 over 5 years of follow-up","volume":"41","author":"Cal\u00e8s","year":"2021","journal-title":"Liver Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/sjg.sjg_586_21","article-title":"Propranolol use in patients with cirrhosis and refractory ascites: a nationwide study","volume":"28","author":"Chen","year":"2022","journal-title":"Saudi J. Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1440-1746.2005.03982.x","article-title":"Spontaneous bacterial peritonitis in cirrhotic patients: is prophylactic propranolol therapy beneficial?","volume":"21","author":"Cholongitas","year":"2006","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/hep.0000000000000858","article-title":"The association between mean arterial pressure and acute kidney injury reversal among patients with decompensated cirrhosis","volume":"81","author":"Cullaro","year":"2025","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/lvt.0000000000000359","article-title":"Outpatient mean arterial pressure: a potentially modifiable risk for acute kidney injury and death among patients with cirrhosis","volume":"30","author":"Cullaro","year":"2024","journal-title":"Liver Transpl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII faculty. Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J. Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s10620-018-5092-6","article-title":"Nonselective beta-blockers do not affect survival in cirrhotic patients with ascites","volume":"63","author":"Facciorusso","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.hbpd.2026.01.010","article-title":"Non-selective beta-blockers control ascites and improve outcomes in cirrhotic patients with first episode of ascites","volume":"25","author":"Fern\u00e1ndez-Soro","year":"2026","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jhep.2019.10.002","article-title":"Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation","volume":"72","author":"Giannelli","year":"2020","journal-title":"J. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1136\/gutjnl-2020-322712","article-title":"Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes","volume":"70","author":"Jachs","year":"2021","journal-title":"Gut"},{"key":"B19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/MCG.0000000000001431","article-title":"Conversion of propranolol to carvedilol improves renal perfusion and outcome in patients with cirrhosis and ascites","volume":"55","author":"Kalambokis","year":"2021","journal-title":"J. Clin. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12072-021-10160-3","article-title":"The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study","volume":"15","author":"Kang","year":"2021","journal-title":"Hepatol. Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/00365521.2014.948053","article-title":"Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature","volume":"50","author":"Kimer","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/gutjnl-2011-301348","article-title":"The window hypothesis: haemodynamic and non-haemodynamic effects of \u03b2-blockers improve survival of patients with cirrhosis during a window in the disease","volume":"61","author":"Krag","year":"2012","journal-title":"Gut"},{"key":"B23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/apt.18188","article-title":"Non-selective beta-blocker is associated with reduced mortality in critically ill patients with cirrhosis: a real-world study","volume":"60","author":"Kumar","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/MEG.0000000000001511","article-title":"Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy","volume":"32","author":"Lee","year":"2020","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/gutjnl-2013-306502","article-title":"Non-selective \u03b2-blockers are associated with improved survival in patients with ascites listed for liver transplantation","volume":"64","author":"Leithead","year":"2015","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.jhep.2016.01.031","article-title":"Keep the sick from harm in spontaneous bacterial peritonitis: dose of beta blockers matters","volume":"64","author":"Madsen","year":"2016","journal-title":"J. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1680\u201390.e1","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective \u03b2 blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jhep.2015.10.018","article-title":"Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure","volume":"64","author":"Mookerjee","year":"2016","journal-title":"J. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.3390\/jcm15041516","article-title":"Nonselective beta blockers are beneficial in patients with cirrhotic ascites and spontaneous bacterial peritonitis: a propensity-matched study","volume":"15","author":"Nawaz","year":"2026","journal-title":"J. Clin. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/liv.13409","article-title":"Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites","volume":"37","author":"Onali","year":"2017","journal-title":"Liver Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serst\u00e9","year":"2010","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1111\/liv.12786","article-title":"The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis","volume":"35","author":"Serst\u00e9","year":"2015","journal-title":"Liver Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s12072-022-10361-4","article-title":"Propranolol vs. band ligation for primary prophylaxis of variceal hemorrhage in cirrhotic patients with ascites: a randomized controlled trial","volume":"16","author":"Singh","year":"2022","journal-title":"Hepatol. Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2017.02.005","article-title":"Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites","volume":"67","author":"Sinha","year":"2017","journal-title":"J. Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/1060028019886529","article-title":"Effect of nonselective \u03b2-Blockers on mortality in patients with end-stage cirrhosis","volume":"54","author":"Snoga","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/jgh.14871","article-title":"Effect of acute kidney injury on long-term outcomes of spontaneous bacterial peritonitis in cirrhotic patients using the international club of Ascites-acute kidney injury criteria","volume":"35","author":"Sohn","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/apt.15439","article-title":"Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis","volume":"50","author":"Tergast","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.gastrohep.2021.02.007","article-title":"Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality","volume":"45","author":"Terres","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"101716","DOI":"10.1016\/j.eclinm.2022.101716","article-title":"Use of non-selective B-blockers is safe in hospitalised decompensated cirrhosis patients and exerts a potential anti-inflammatory effect: data from the ATTIRE trial","volume":"55","author":"Tittanegro","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/apt.18261","article-title":"Impact of non-selective beta blockers on further decompensation and death in decompensated cirrhosis: benefit and risk stratification by MELD score","volume":"60","author":"Wang","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/liv.14040","article-title":"Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: a meta-analysis","volume":"39","author":"Wong","year":"2019","journal-title":"Liver Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/ueg2.12739","article-title":"Secondary prophylaxis of cirrhotic gastric variceal bleeding: addition of non-selective beta-blockers to endoscopic combined treatment","volume":"13","author":"Wu","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2305935","DOI":"10.1080\/07853890.2024.2305935","article-title":"Association of non-selective \u03b2 blockers with the development of renal dysfunction in liver cirrhosis: a systematic review and meta-analysis","volume":"56","author":"Xu","year":"2024","journal-title":"Ann. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"909455","DOI":"10.3389\/fpubh.2022.909455","article-title":"The burden of liver cirrhosis in mortality: results from the global burden of disease study","volume":"10","author":"Ye","year":"2022","journal-title":"Front. Public Health"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e18913","DOI":"10.1097\/MD.0000000000018913","article-title":"Propranolol plus endoscopic ligation for variceal bleeding in patients with significant ascites: propensity score matching analysis","volume":"99","author":"Yoo","year":"2020","journal-title":"Med. Baltim."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1920788\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:31:15Z","timestamp":1785918675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1920788\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":45,"alternative-id":["10.3389\/fphar.2026.1920788"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1920788","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1920788"}}